Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 5/2015

01-05-2015 | Original Article - Cases with a Message

Cat scratch disease during infliximab therapy: a case report and literature review

Authors: Yi Zhou, Geng Yin, Chunyu Tan, Yi Liu

Published in: Rheumatology International | Issue 5/2015

Login to get access

Abstract

Cat scratch disease may occur during etanercept therapy, but there has been no report on infliximab-associated cat scratch disease. We report a case of a 23-year-old woman who developed right inguinal lymph node enlargement following a cat scratch. The patient had received infliximab therapy for spondyloarthropathy. She was successfully managed by discontinuing infliximab and by treatment with moxifloxacin and amikacin.
Literature
1.
Wiedmann MW, Mössner J et al (2009) TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr Metab Immune Disord Drug Targets 9:295–314CrossRefPubMed
2.
Hofland RW, Thijsen SF et al (2013) Tuberculosis during TNF-α inhibitor therapy, despite screening. Thorax 68:1079–1080CrossRefPubMed
3.
Schiffmann A, Pers YM, Lukas C et al (2009) Mesenteric and splenic cat-scratch disease during etanercept therapy. Rheumatology 48:1461–1462CrossRefPubMed
4.
Mathieu S, Vellin JF, Poujol D et al (2007) Cat scratch disease during etanercept therapy. Joint Bone Spine 74:184–186CrossRefPubMed
5.
Osorio F, Pedrosa A, Azevedo F et al (2014) Cat scratch disease during anti-tumor necrosis factor-alpha therapy: case report and review of literature. Int J Dermatol 53(3):e182–e183CrossRefPubMed
6.
Massei F, Gori L, Macchia P et al (2005) The expanded spectrum of bartonellosis in children. Infect Dis Clin North Am 19(3):691–711CrossRefPubMed
7.
Black JR, Herrington DA (1986) Life-threatening cat-scratch disease in an immunocompromised host. Arch Intern Med 146(2):394–396CrossRefPubMed
8.
Jain A, Sinqn JA (2013) Harms of tumor necrosis factor inhibitors in rheumatic diseases: a focused systematic review of the literature. Immunotherapy 5:265–299CrossRefPubMedCentralPubMed
9.
Baeten D, Kruithof E, Van den Bosch F et al (2003) Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease? Ann Rheum Dis 62:829–834CrossRefPubMedCentralPubMed
10.
Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265CrossRefPubMed
11.
Carithers HA (1985) Cat-scratch disease. An overview based on a study of 1,200 patients. Am J Dis Child 139(11):1124–1133CrossRefPubMed
12.
Rolain JM, Brouqui P, Koehler JE et al (2004) Recommendations for treatment of human infections caused by bartonella species. Antimicrob Agents Chemother 48:1921–1933CrossRefPubMedCentralPubMed
Metadata
Title
Cat scratch disease during infliximab therapy: a case report and literature review
Authors
Yi Zhou
Geng Yin
Chunyu Tan
Yi Liu
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3204-y

Other articles of this Issue 5/2015

Rheumatology International 5/2015 Go to the issue

Original Article - Observational Research

The clinical burden of generalized osteoarthritis represented by self-reported health-related quality of life and activity limitations: a cross-sectional study

Original Article - Imaging

Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions

Original Article - Observational Research

Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience

Original Article - Cases with a Message

Osseous sarcoidosis: a case series

Original Article - Observational Research

Does rheumatoid arthritis disease activity correlate with weather conditions?

Short Communication - Observational Research

Association of cardiorespiratory fitness with pressure pain sensitivity and clinical pain in women with fibromyalgia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits